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Abstract 
When the graft volume is too small to satisfy the recipient’s metabolic demand 
(“small-for-size graft”: SFSG), the recipient may thus experience “small-for-size 
syndrome” (SFSS). Because the occurrence of SFSS is determined by not only the liver 
graft volume but also a combination of multiple negative factors, the definitions of SFSG 
and SFSS are different in each institute and at each time. 
In the clinical setting, surgical inflow modulation and maximizing the graft outflow are 
keys to overcoming SFSS. Accordingly, relatively smaller-sized grafts can be used with 
surgical modification and pharmacological manipulation targeting portal circulation and 
liver graft quality. Therefore, the focus of the SFSG issue is now shifting from how to 
obtain a larger graft from the living donor to how to manage the use of a smaller graft to 
save the recipient, considering donor safety to be a priority.  
  
Introduction 
In the last 20 years, the indications for living-donor liver transplantation (LDLT) have 
been successfully expanded from pediatric to adult cases. However, the use of grafts 
smaller than the native liver is unavoidable in cases of LDLT performed on adults. When 
the graft volume is too small to satisfy the recipient’s metabolic demand (“small-for-size 
graft”: SFSG), the recipient may thus experience “small-for-size syndrome” (SFSS). 
“SFSS” is characterized clinically by a combination of prolonged functional cholestasis, 
intractable ascites, and delayed functional recovery of both prothrombin time and 
encephalopathy (1-3). To avoid SFSG, the use of a larger-sized graft, such as the right 
lobe graft, is the standard strategy for adult-to-adult LDLT (4-7). However, although a 
right-lobe LDLT can provide an adequate graft size to meet the metabolic demands of 
most adult recipients, “SFSS” can be observed not only in “SFSG” recipients but also in 
larger-sized graft recipients (8-10). Therefore, the occurrence of SFSS is determined by 
not only the liver graft volume but also a combination of multiple negative factors. 
However, the procurement of a liver graft of greater volume imposes a greater risk on the 
donor because the remaining portion of the liver in the donor is smaller. Accordingly, the 
criteria for SFSG in adult-to-adult LDLT have been revised recently at several institutes 
(2, 11). In other words, a relatively smaller-sized graft, such as the left lobe, can be used in 
adults with surgical manipulations aimed at reducing the portal venous pressure (PVP) 
and flow (PVF) (11, 12). Therefore, the focus of the SFSG issue is now shifting from how 
to obtain a larger graft from the living donor to how to manage the use of a smaller graft to 
save the recipient, considering donor safety to be a priority. 
Definition 
Kiuchi et al. (1) defined “SFSG” as a < 0.8% graft-to-recipient body weight ratio 
(GRWR). They reported that the use of “SFSG” leads to “SFSS,” including poor bile 
production, delayed synthetic function, prolonged cholestasis and intractable ascites, with 
subsequent septic complications and higher mortality. Sugawara et al. (13) suggested that 
a graft volume/standard liver volume ratio (GV/SLV) < 40% was associated with 
decreased survival and the prolonged recovery of liver function. At present, some 
institutes have established criteria for graft selection with a lower GRWR than before: 
GRWR > 0.8% (14, 15) or GRWR > 0.6% in combination with PVP control (11); these 
criteria show that the definition of “SFSG” has become lower in LDLT. Although there 
has been no accepted definition of “SFSS” until now, several different definitions for 
SFSS or liver graft dysfunction have been given (3, 16-18) (Table 1).  
Pathophysiology 
I. Relative shortage of vital liver volume for life maintenance 
The first possibility of the pathogenesis of poor prognosis in SFSG is the relative shortage 
of hepatic parenchymal cells. Previous clinical analyses have suggested that a normal 
liver can tolerate a partial hepatectomy to 25 - 27 % of the residual volume (19-21). 
II. Portal hypertension: shear stress 
The characteristic microscopic findings of SFSS, including hepatocyte ballooning and 
cholestasis, are thought to be due to microcirculatory disturbances (22). Many 
experimental and clinical studies (12, 23-28) suggest that elevated PVP (shear stress) 
forms the central pathogenesis of SFSS. A persistent elevation of the PVP in the graft, 
which is attributable to hyperdynamic splanchnic circulation (29) and limited 
accommodation of the graft, causes sinusoidal endothelial cell injury (25) and the release 
of deleterious mediators (30), which ultimately lead to serious graft injury. Shear stress 
also leads to an imbalance in the expression of intragraft vasoregulatory genes, such as 
endothelin-1 and nitric oxide (31). Microcirculatory disorders in SFSG will eventually 
result in graft dysfunction (32).  
III. Arterial hypoperfusion 
The role of arterial hypoperfusion in SFSS is less well studied as it is secondary to portal 
hyperperfusion. Low hepatic artery flow is considered to be due to a homeostatic 
mechanism known as the hepatic arterial buffer response (33). In states of extreme portal 
hyperperfusion, such as those observed in SFSG, an exaggerated hepatic arterial buffer 
response may contribute to ischemic injury, ischemic cholangitis, and cholestasis. 
IV. Intestinal mucosal injury 
We demonstrated that the intestinal mucosa was severely damaged with portal 
hypertension following SFSG liver transplantation in swine (26). Several experimental 
studies (34-39) have revealed that portal hypertension in liver cirrhosis can increase 
bacterial translocation by inducing congestion and edema of the intestine. Accordingly, 
bacterial translocation could be developed in an SFSG-transplanted recipient due to the 
elevation of mucosal permeability, which is compatible with the clinical aspect of a 
higher postoperative infection rate in SFSS (40). 
V. Liver regeneration 
After extensive hepatectomy or segmental liver transplantation with an SFSG, liver 
regeneration is essential for patient survival. Liver regeneration is a highly complex and 
organized process that has been shown to involve the actions of a number of cytokines 
and growth factors, such as hepatocyte growth factor (HGF) (41), transforming growth 
factor- (42), epidermal growth factor (43), hepatocyte growth factor activator (HGFA) 
(44) and vascular endothelial growth factor (VEGF) (45). Shear stress is well defined as a 
putative trigger mechanism for liver regeneration (46-48). During the first week after a 
partial liver transplantation, the partial liver graft regenerates quickly, up to 
approximately 80-100% compared with the standard liver volume (47). Ninomiya et al. 
(49) showed that SFSGs regenerated faster and were associated with significantly higher 
peripheral HGF levels one day after LDLT than non-SFSGs. Many previous studies have 
suggested that the elevation of PVF or shear stress induces liver regeneration and that 
insufficient PVF induces hepatic atrophy and liver failure (50-57). Portal hyperperfusion 
can promote liver regeneration only if it is limited to a certain extent. Hessheimer et al. 
(58) suggested that the liver graft requires PVF superior to its normal baseline value for 
liver regeneration and that a calibrated portocaval shunt (PCS) that maintains the PVF at 
twice its baseline value produces a favorable outcome after swine liver transplantation 
with a 30% SFSG.  
Clinical Factors influencing SFSS 
I. Quality of the graft 
Factors regulating liver graft compliance would be the potential definition of the graft 
quality, such as donor age, steatosis, and ischemic injury. Other unknown factors may 
also precipitate SFSS. 
a. Ischemic injury  
Both warm (59) and cold ischemia (60) have been shown to impair regeneration after 
partial liver transplantation. The difference in the essential liver volume after the 
operation between an extended hepatectomy and partial liver transplantation may owe 
much to the existence of this issue.  
b. Steatosis 
A steatotic liver graft from a deceased donor with a longer cold ischemic time is well 
known to be associated with poor graft function and survival. A previous study revealed 
that steatotic liver grafts are related to the increased susceptibility to ischemia-reperfusion 
injury (61, 62), including impaired graft microcirculation and PVF, increased 
hepatocellular damage observed serologically and histologically, increased 
pro-inflammatory cytokine production, and decreased ATP concentration. However, in an 
LDLT setting with a shorter cold ischemic time compared with a deceased donor graft, 
Hayashi et al. (63) reported that early graft function after LDLT was similar in mild and 
moderate steatosis but that severe steatosis was significantly associated with poor graft 
function and survival. In any case, SFSS is determined by a combination of multiple 
negative factors, and steatotic liver grafts should be avoided if the graft volume is small. 
c. Donor age  
Moon et al. (64) have shown that an older donor age affects graft prognosis only when 
combined with an SFSG. Ikegami et al. (65) reported that the function and regeneration of 
the allografts from older donors in LDLT are worse than those of their younger 
counterparts. Tanemura et al. also (66) reported that donor age (≥ 50 years) was 
independently correlated with impaired remnant liver regeneration at 6 months in right 
lobe LDLT.  
d. Congestion 
The magnitude of the impact of tissue congestion caused by interrupted venous drainage 
is highly variable among grafts. Severe congestion in the anterior segment has been 
reported to occur in right lobe grafts without the middle hepatic vein, which leads to 
massive ascites and graft dysfunction (8). 
II. Perioperative recipient related factors 
A. Preoperative recipient status:  
With respect to the maintenance of the initial graft function, the post-transplant metabolic 
and synthetic demands in recipients with severely damaged liver function 
(hyperbilirubinemia, coagulopathy) and a pre-operative deteriorated general condition 
(renal dysfunction, septic state, etc.) aggravate the metabolic function of the graft (1, 67). 
Furthermore, the liver grafts may be insufficiently functional for the excessive metabolic 
and synthetic demands of high-risk recipients, including their reduced metabolic and 
synthetic capacities. Therefore, a pre-operative deteriorated condition with a high model 
for endstage liver disease (MELD) score may impair the function of the graft, leading to 
graft dysfunction, graft failure and eventually multiple organ failure, especially in SFSG. 
Yoshizumi et al. (68) reported that a larger graft is necessary if the donor age is > 50 years 
and the MELD score is >20. Accordingly, Ikegami et al. (69) recommended that high-risk 
patients should receive a larger, younger graft to minimize the risk of SFSS. 
B. Portal circulation (Pressure and Flow):  
After LDLT, Ogura et al. (70) demonstrated that a PVP <15 mmHg is associated with 
good patient outcome in a retrospective clinical analysis: patients with a PVP <15 mmHg 
demonstrated a better 2-year survival (93.0%) than patients with a portal pressure ≥15 
mmHg (66.3%).  
Hessheimer et al. (58) reported that the PV-inferior vena cava (IVC) pressure gradient and 
PVP were significantly higher in SFSG liver transplantation in swine and that the PCS 
decreased both the PVP and PV-IVC pressure gradients. However, Ogura et al. (12) 
reported in a retrospective clinical study of LDLT that although the PV-IVC pressure 
gradient was higher in the group with the higher PVP, there were no significant 
differences in the 1- and 3-year survival rates when they divided and analyzed their study 
group by low (< 9 mm Hg) and high (≥ 9 mm Hg) PV-IVC pressure gradients. Further 
experiments or clinical trials of SFSG are necessary to determine whether the PVP or 
PV-IVC pressure gradient is more significant for SFSG. 
In clinical research, we showed that a high compliance (PVF/PVP) graft in which the 
PVF can be maintained at a high level despite a low PVP is a good graft for postoperative 
liver graft function (71). The optimal portal venous circulation for the liver graft could 
depend on the graft size and quality.  
Intervention to avoid SFSS 
(1) Graft selection: increase the graft volume and maximize the outflow 
After the concept of “SFSS” had been reported, the graft type shifted from the left side to 
the right side of the liver to increase the liver graft volume. Dual graft liver 
transplantation was also proposed when two donors were available in some institutes (72, 
73).  
Regarding the usage of a “right-side graft”, to avoid the development of a congested area 
in the anterior segment, some institutes have preferred to use a “with MHV graft”. Fan et 
al. chose an extended right-lobe graft with the MHV (74). In contrast, the additional 
venous reconstruction of the anterior segment with an interposition vein graft has been 
adopted by Lee et al. (8). The reconstruction of the segment V and VIII branches using 
jump grafts has been reported (75). In our institute, we have performed the venous 
reconstruction of the anterior segment together with an anterior patch plasty of the hepatic 
vein using the native portal vein to maximize the liver graft outflow (76).  
We reported that the compliance per unit of graft weight in left-lobe grafts is higher than 
in right lobe grafts without MHV in LDLT (71). Shimada et al. (77) also reported that 
left-lobe grafts are a feasible option for LDLT because the outflow of the left-lobe graft is 
considered superior to that of the right-lobe graft and in the case of right-lobe grafts 
without the MHV, hepatic venous drainage is one of the most critical problems. 
Accordingly, beginning in December 2007, our institution has actively selected the 
left-lobe graft for use in LDLT to maximize the graft outflow and minimize the risks to 
the healthy donor. 
(2) Portal inflow modulation 
Boilot et al. (78) first reported a case in which a recipient-transplanted SFSG with a 
GRWR of 0.61% was successfully treated by the reduction of PVP with a mesocaval 
shunt. Thereafter, several surgeons have reported the successful treatment of SFSG by 
surgical manipulations to reduce the PVP and PVF with a splenic arterial ligation (28), 
PCS (27, 79, 80) or splenectomy (12, 81-83) in clinical and animal studies (84, 85).  
However, because the diversion of portal inflow can lead to liver necrosis or atrophy, an 
adequate PVF is essential for liver regeneration (26, 52, 58). We reported that an 
SFSG-transplanted swine with a large PCS could not survive more than 5 days after liver 
transplantation, with its autopsy showing massive hepatic necrosis. A large PCS, which 
would greatly reduce the PVF and therefore result in graft failure, should be avoided (26).  
Therefore, in our institution, a splenectomy is performed first to decrease the PVP (< 15 
mmHg), and all large collaterals are ligated to prevent the steal phenomenon in some 
situations, which decrease the compliance after LDLT (such as rejection) (83).  
(3) Other interventions 
In experimental research, several pharmacological interventions have been reported to 
improve the survival after SFSG, including the portal infusion of prostaglandin E1 (86), 
granulocyte colony-stimulating factor (87), endothelin A receptor antagonist (31), redox 
factor-1 (88), somatostatin (89), and hyperbaric oxygen treatment (90) to promote liver 
regeneration or reduce ischemia-reperfusion injury after an SFSG liver transplantation. 
(4) Organ preservation 
Newly developed preservation solutions, such as POLYSOL (32), activated protein C 
(91) in preservation solution, and cold preservation using retrograde nitric oxide with 
oxygen administration, for SFSG liver transplantation (92) were reported to recondition 
the liver graft viability and promote liver regeneration in rats. 
Conclusion 
SFSG has become an issue again with respect to pursuing donor safety. Because the 
occurrence of SFSS is determined by not only the liver graft volume but also a 
combination of multiple negative factors, we should manage all risk factors and make 
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, 2005  Small-for-size dysfunction (SFSD) 
Dysfunction* of a ‘small’ partial liver graft (GRWR < 0.8%) during the 
first postoperative week after the exclusion of other causes***. 
Small-for-size non-function (SFSNF) 
Failure**of a ‘small’ partial liver graft (GRWR < 0.8%) during the first 




, 2006  Small for size syndrome 
Prolonged cholestatis (T.Bil >10 mg/dL on POD14) and intractable 




, 2009 Small for size syndrome 
T.Bil >10 mg/dL (and continuing to increase) after POD 7, PT-INR >1.5 
and ascites >2 L, excluding mechanical/technical problems. 
Ikegami et al.
18)
, 2012 Delayed functional hyperbilirubinemia (DFH)  
with T.Bil >20 mg/dL  
For >seven consecutive days   after POD 7, excluding technical, 
immunological and hepatitis factors. 
∗  Graft dysfunction = the presence of two of the following on three consecutive days: 
bilirubin >100 lmol/l, INR > 2, encephalopathy grade 3 or 4.     
∗ ∗  Graft failure = re-transplantation or death of recipient.  
∗ ∗ ∗  Exclusion criteria: technical (e.g. arterial or portal occlusion, outflow congestion, 
bile leak), immunological (e.g. rejection), infectious (e.g. cholangitis, sepsis). 
 
 
